Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension
(CTEPH) are serious diseases with poor prognosis despite recent advances. Currently,
pulmonary hypertension (PH) is considered a cell proliferative disorder, which has not been
adequately characterized due to the lack of markers. A better understanding of the mechanisms
that regulate this proliferative disorder will allow the identification of new therapeutic
targets for HP.
The objective of the project is to identify cell proliferative processes in severe forms of
PH. Patients with PAH (n=20), CTEPH (n=20) and healthy controls (n=20) will undergo
characterization of microRNAs (miRNAs) contained within circulating microparticles (MPs)
analysis and mitochondrial functionality and FDG-PET to compare cell metabolism in the lungs
and the right ventricle between patients and controls.